Be the first person to write a business review for CGI Pharmaceuticals, Inc.

Champions Biotechnology, Inc. company was founded in 1985 and is based in Baltimore, Maryland. Champions Biotechnology, Inc., a biotechnology company, engages in the development of advanced preclinical platforms and predictive tumor specific data to enhance the value of oncology drugs in the United States. Its preclinical platform is an approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts) in a manner that preserves the biological characteristics of the original human tumor. The company leverages its preclinical platform to evaluate and develop a portfolio of oncology drug candidates through preclinical trials; and plans to sell, partner or license such drug candidates to pharmaceutical and/or biotechnology companies.Champions Biotechnology provides Personalized Oncology Services to physicians in the field of oncology by establishing and administering expert medical information panels for their patients to analyze medical records and test results; to assist in understanding conventional and experimental options; and to identify and arrange for testing, analysis, and study of the patients cancer tissues. In addition, the company offers personalized Tumorgraft development and drug studies to physicians for evaluating the effects of cancer therapies on their patient's. It offers its platform and tumor specific data to other biotechnology and pharmaceutical companies. The company was formerly known as Champions Sports, Inc. and changed its name to Champions Biotechnology, Inc. in January 2007 as a result of change in its business focus towards biotechnology.

Charles River Laboratories International, Inc. company was founded in 1947 and is headquartered in Wilmington, Massachusetts. Charles River Laboratories International, Inc. provides research models and laboratory animal support expertise to help its global partners advance their research and drug development efforts. The company offers a portfolio of services to support discovery and imaging, preclinical and early-phase clinical studies, and biopharmaceutical and endotoxin products and services for manufacturing and quality control. Its portfolio spans the entire research and drug development process, from IND consultation to discovery through market approval, allowing customized approaches to support both single-study or broad-based programs. Charles River Laboratories International serves pharmaceutical and biotechnology companies, as well as government agencies, hospitals, and academic institutions.

Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina. Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. It offers droxidopa, an orally active synthetic precursor of norepinephrine, which is in two double-blind pivotal Phase III trials for the treatment of symptomatic neurogenic orthostatic hypotension, freezing gait in Parkinson's disease, and intradialytic hypotension; for the treatment of intradialytic hypotension for which it has completed a double-blind placebo controlled Phase II study; and for the treatment of fibromyalgia that is in a Phase II trial.Chelsea Therapeutics company also offers a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, such as a portfolio of metabolically inert antifolate molecules, including CH-1504 for the treatment of rheumatoid arthritis that is in a Phase II head-to-head clinical trial; and CH-4051, which is in the Phase I study designed to determine the maximum tolerated dose based on results of single-ascending and multiple-ascending dose evaluations. In addition, it develops antifolate program, a second platform consisting of a portfolio of dihydroorotate dehydrogenase(DHODH), inhibiting compounds known as the I-3D portfolio, a group of orally active compounds that inhibit the enzyme DHODH for the treatment of immune-mediated inflammatory disorders, including transplant rejection, autoimmune diseases, psoriasis, and systemic lupus erythematosus.

ChemGenex Pharmaceuticals is looking for treatments that are tailor-made for different patients. The company is researching targeted cancer therapies, finding genetic differences that affect how well patients respond to certain drugs and tailoring therapies accordingly. Its lead candidate is omacetaxine mepesuccinate (formerly called Ceflatonin); the drug is undergoing clinical testing as a treatment for chronic myeloid leukemia in patients who have a genetic mutation that makes them resistant to Novartis' Gleevec. Also in clinical development is Quinamed, a potential tumor fighter. The company has several other preclinical oncology programs as well.

ChemOvation offers contract drug discovery research and design services to pharmaceutical and biotechnology companies. ChemOvation has expertise in organic and medicinal chemistry, and drug discovery. ChemOvation also provides protein binding and compound solubility measurements for clients' metabolism research. ChemOvation's team of contractors is built around a core of organic chemists and technicians. Formed in 1999, the company merged with KuDOS Pharmaceuticals in 2000. ChemOvation dissolved those bonds in 2005 having spun off from KuDOS and is independent once again.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.